Literature DB >> 18227354

Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment.

Tomohito Inage1, Teruhisa Yoshida, Tatsuro Hiraki, Masatsugu Ohe, Tomohiro Takeuchi, Yasutsugu Nagamoto, Yujiro Fukuda, Takeki Gondo, Tsutomu Imaizumi.   

Abstract

AIMS: The aim of this study was to assess chronic invasive haemodynamic effects of cardiac resynchronization therapy (CRT) in patients with severe heart failure. METHODS AND
RESULTS: Seventeen patients with New York Heart Association (NYHA) class III or IV and QRS duration >120 ms on optimal treatments underwent CRT. Haemodynamic data were obtained by cardiac catheterization before and 1 month after CRT. Clinical parameters and exercise tolerance were also evaluated. Chronic CRT improved haemodynamics significantly; mean pulmonary capillary wedge pressure decreased from 15.9 +/- 6.1 to 10.2 +/- 5.3 mmHg (P < 0.05), systolic pulmonary artery pressure decreased from 36.5 +/- 13.2 to 26.7 +/- 11.9 mmHg (P < 0.05), left ventricular end-diastolic pressure decreased from 15.6 +/- 7.2 to 10.5 +/- 7.3 mmHg (P < 0.05), end-diastolic volume decreased from 358.8 +/- 84.6 to 322.9 +/- 99.0 mL (P < 0.05), end-systolic volume decreased from 264.1 +/- 67.6 to 219.2 +/- 74.3 mL (P < 0.05), left ventricular ejection fraction increased from 25.4 +/- 6.2 to 33.1 +/- 4.9% (P < 0.05), and cardiac index increased from 1.9 +/- 0.4 to 2.2 +/- 0.5 L/min/m(2) (P < 0.05). Chronic CRT significantly improved functional capacity such as NYHA classification, 6 min walk distance, and peak oxygen uptake.
CONCLUSION: Chronic CRT improved not only symptoms and exercise tolerance but also invasive haemodynamics associated with reversed cardiac remodelling.

Entities:  

Mesh:

Year:  2008        PMID: 18227354     DOI: 10.1093/europace/eum297

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

1.  Cardiac Resynchronization Therapy in CKD Stage 4 Patients.

Authors:  Ulas Höke; Mand J H Khidir; Enno T van der Velde; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

2.  Cardiac resynchronization therapy in the cardiorenal syndrome.

Authors:  Margot K Davis; Sean A Virani
Journal:  Int J Nephrol       Date:  2011-06-09

Review 3.  Impact of baseline renal function on all-cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and meta-analysis.

Authors:  G Bazoukis; K P Letsas; P Korantzopoulos; C Thomopoulos; K Vlachos; S Georgopoulos; N Karamichalakis; A Saplaouras; M Efremidis; A Sideris
Journal:  J Arrhythm       Date:  2017-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.